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The use of antihuman T-lymphocyte immunoglobulin in the setting oftransplantation from an HLA-matched related donor is still muchdebated. Acute and chronic graft-versus-host disease are the main
causes of morbidity and mortality after allogeneic hematopoietic stem cell
transplantation in patients with myelofibrosis. The aim of this study was to
evaluate the effect of antihuman T-lymphocyte immunoglobulin in a large
cohort of patients with myelofibrosis (n=287). The cumulative incidences
of grade II-IV acute graft-versus-host disease among patients who were or
were not given antihuman T-lymphocyte immunoglobulin were 26% and
41%, respectively. The corresponding incidences of chronic graft-versus-
host disease were 52% and 55%, respectively. Non-adjusted overall sur-
vival, disease-free survival and non-relapse mortality rates were 55% versus
53%, 49% versus 45%, and 32% versus 31%, respectively, among the
patients who were or were not given antihuman T-lymphocyte
immunoglobulin. An adjusted model confirmed that the risk of acute graft-
versus-host disease was lower following antihuman T-lymphocyte
immunoglobulin (hazard ratio, 0.54; P=0.010) while it did not decrease the
risk of chronic graft-versus-host disease. The hazard ratios for overall sur-
vival and non-relapse mortality were 0.66 and 0.64, with P-values of 0.05
and 0.09, respectively. Antihuman T-lymphocyte immunoglobulin did not
influence disease-free survival, graft-versus-host disease, relapse-free sur-
vival or relapse risk. In conclusion, in the setting of matched related trans-
plantation in myelofibrosis patients, this study demonstrates that antihu-
man T-lymphocyte immunoglobulin decreases the risk of acute graft-versus-
host disease without increasing the risk of relapse.
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ABSTRACT
Introduction
Primary myelofibrosis and myelofibrosis secondary to
polycythemia vera or essential thrombocythemia are
myeloproliferative neoplasms characterized by progres-
sive fibrosis of the bone marrow and myeloid metaplasia
in the spleen and liver. Disease severity can be assessed
by a number of different prognostic scoring systems,
which are able to predict survival without treatment in
patients with primary and secondary myelofibrosis.1–5
The risk factors usually taken into account in these scores
are disease-related symptoms, the degree of cytopenia or
hyperleukocytosis, peripheral or bone marrow blast
excess and age. Moreover, cytogenetics and somatic
mutations provide additional prognostic power to these
scoring instruments.3,6–9 According to the number of risk
factors, the expected median survival from diagnosis can
range from more than 10 years to less than 18 months.
Allogeneic hematopoietic stem cell transplantation
(HSCT) remains the only curative treatment in patients
with myelofibrosis. One registry-based study demon-
strated that patients with intermediate-2- or high-risk dis-
ease according to the Dynamic International Prognostic
Scoring System (DIPSS) have an advantage in overall sur-
vival following transplantation and international expert
consensus guidelines are in favor of transplantation in
such patients.10,11 Cumulatively, overall survival after
HSCT can range between 40% and 65% according to risk
factors related to the disease, patient and type of donor.12–
18 Results have been considered better with transplant
from an HLA-matched sibling donor than an unrelated
donor. However, acute and chronic graft-versus-host dis-
ease (GvHD) remain frequent causes of death in patients
with myelofibrosis undergoing HSCT, often contributing
to a relatively high transplant-related mortality of around
30%.12–18 The optimal conditioning regimen and GvHD
prophylaxis in these patients remain unknown. Two
prospective studies of HSCT in myelofibrosis, in which
the conditioning regimen and GvHD prophylaxis strate-
gies were homogeneous, can be considered to compare
GvHD rates and outcomes. In 2009, Kröger et al. reported
on 103 myelofibrosis patients given conditioning with
fludarabine, busulfan and the antihuman T-lymphocyte
immune globulin Grafalon® at a dose of 30 mg/kg when
the graft was from a matched related donor and 60 mg/kg
when the donor was unrelated, combined with
cyclosporine and a short course of methotrexate. With
this regimen, including in vivo T-cell depletion, the rate of
acute grade II-IV GvHD was relatively low (27%) and the
incidence of chronic GvHD was 49%. The relapse inci-
dence was 32% in the setting of a matched related donor
and 20% with an unrelated donor; these incidences were
not statistically significantly different. Rondelli et al. sub-
sequently reported a second prospective trial regarding
HSCT in myelofibrosis using a fludarabine and melpha-
lan platform in patients transplanted from a matched
related donor, with the addition of Thymoglobulin® in
patients with an unrelated donor.17 Acute GvHD rates
were substantial, being 38% and 41% in the sibling
donor group and unrelated donor group, respectively.
Chronic GvHD rates did not differ significantly between
the sibling donor (36%) and unrelated donor (38%)
groups. Of particular note, mortality was dramatically
higher (68%) in the group of patients who underwent
unrelated donor HSCT but the effect of antilymphocyte
globulin (ATG) on this higher mortality risk remains
undetermined. Collectively, from these two studies, it
cannot be concluded unambiguously that ATG is benefi-
cial in the setting of transplantation from a matched relat-
ed donor. Recently, a randomized trial showed that ATG
prevents chronic GvHD in patients with acute lymphoid
leukemia or acute myeloid leukemia undergoing trans-
plantation from an HLA-matched sibling donor following
myeloablative conditioning regimens.19 Indeed, while
acute GvHD was non-significantly lowered, the cumula-
tive incidence of chronic GvHD dropped from 69% with-
out ATG to 32% with Grafalon® without increasing the
risk of relapse. In this large European Society for Blood
and Marrow Transplantation (EBMT) cohort, we aimed
to determine the effect of ATG in the setting of HSCT for
myelofibrosis using an HLA-matched sibling donor,
which is of particular importance as data remain scarce
given the rarity of the disease.
Methods
Consecutive patients transplanted from a matched sibling
donor without ex vivo graft manipulation between 2007 and
2015 for myelofibrosis and registered in the EBMT registry were
included in this study. Patients who received post-transplant
treatment with cyclophosphamide or alemtuzumab as GvHD
prophylaxis and those without sufficient information regarding
blood cell counts prior to transplantation were excluded. A total
of 287 patients were selected for the final analysis, among
whom 135 received in vivo T-cell depletion while 152 did not.
The DIPSS was calculated according to the original definition.1
For some patients the data on peripheral blast count at the time
of transplantation were missing; in these cases, the diagnostic
blast count was used. General symptoms were either weight
loss or sweating (only 2 patients had fever); data on constitution-
al symptoms were missing for 50 patients. Because information
on the brand of drug used for T-cell depletion was not available
in the registry, a stepwise hypothetical strategy was formulated
to identify patients who received Thymoglobulin® and those
who had received Grafalon®: ATG doses of 10 mg/kg or lower
were considered as Thymoglobulin® whereas doses of 20 mg/kg
or higher were considered as Grafalon® based on usual doses of
each brand. This strategy was also checked by country in which
the HSCT was performed, as some countries used only
Grafalon®, others used only Thymoglobulin® and some used
both products. 
Disease-free survival was defined as survival without disease
relapse or progression documented in the registry. GvHD-free,
relapse-free survival (GRFS) was defined as survival without dis-
ease relapse or progression, without grade III-IV acute GvHD
and without chronic extensive GvHD documented in the reg-
istry.
Failure time data were analyzed used Kaplan-Meier estimates,
log-rank tests and Cox modeling unless competing risks existed,
when cumulative incidence curves, the Gray test and cause-spe-
cific Cox models were used.20 When estimating the cumulative
incidence of chronic GvHD, patients were censored at the time
of donor lymphocyte infusion, as previously reported. Based on
frailty models,21 we tested whether there was a center effect on
each outcome.  
The study complied with regulatory requirements, the decla-
ration of Helsinki and Good Practice standards. Independent
review boards approved the study. Patients gave written
informed consent.
ATG in myelofibrosis patients
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Results
Patients and transplant characteristics
The main patient, disease and transplant characteristics
are described in Table 1. The median age of the partici-
pants was 56.9 years [interquartile range (IQR), 50.6-61.5
years], the minimum was 22.1 years and the maximum
was 75.5 years. There was a majority of male patients
(68%). Patients who were not given ATG (n=152) and
those who were (n=135) had similar characteristics
regarding age, gender, and type of myelofibrosis (primary
or secondary) but differed for other characteristics includ-
ing splenectomy before transplant (38% versus 9%), DIPSS
classification (intermediate-2 or high: 59% versus 68%),
conditioning regimen (Table 1) and source of stem cells
(bone marrow 17% versus 2%). More patients in the ATG
group received calcineurin inhibitors alone (26% versus
7%). Concerning pre-transplant therapy, five patients in
the non-ATG cohort and 14 in the ATG cohort received
the JAK inhibitor ruxolitinib (Novartis Pharmaceuticals,
Geneva, Switzerland). Regarding the brand of ATG used
in the ATG group, 37 patients received Grafalon®, 96
received Thymoglobulin® and the brand was undeter-
mined for two patients. 
Engraftment
Six patients had primary graft rejection (3 in the ATG
group and 3 in the non-ATG group). Four of these patients
received a second HSCT and three of them were alive and
in remission at the time of last reported follow-up. The
cumulative incidences of neutrophil engraftment at day 60
were 96.3% [95% confidence interval (95% CI): 90.9%-
98.5%] and 94.1% (95% CI: 88.7%-96.9%) for the groups
not given or given ATG, respectively (P=0.35). The corre-
sponding cumulative incidences of platelet recovery at 6
months were 68.4% (95% CI: 60.3%-75.2%) and 80.3%
(95% CI: 72.3%-86.1%) (P=0.09). Twenty-four patients
(14 in the ATG group and 10 in the non-ATG group) had
a secondary rejection at a median time of 9 months fol-
lowing HSCT and all but one had disease progression.
Half of them received a second HSCT, which failed to
achieve a remission.
Outcomes
The median time to onset of acute GvHD was 36 days.
The cumulative incidence of grade II-IV acute GvHD was
significantly higher in the group of patients who did
receive ATG than in the group of patients who did not:
41.4% (95% CI: 33.1%-49.5%) versus 26.2% (95% CI:
18.7%-34.3%) (P=0.0067) whereas the incidence of grade
III-IV GvHD was similar in both groups (Figure 1). The
median time to develop chronic GvHD was 198 days. The
incidence of chronic GVHD was high (>50%) in both
groups of patients (Figure 1) without there being signifi-
cant differences according to whether or not ATG was
administered. Rates of chronic extensive GvHD were also
similar in the two groups. The cumulative incidence of
relapse was 24.4% (95% CI: 16.5%-33.1%) after ATG and
18.6% (95% CI: 12.1%-26.1%) without ATG (P=0.083).
The rate of non-relapse mortality was 32.5% (95% CI:
24.4%-40.7%) with ATG versus 31% (95% CI: 20.9%-
41.6%) without ATG. During the follow-up period, a total
of 65 patients in the non-ATG group and 44 in the ATG
group died. The primary cause of death was related to
myelofibrosis progression in 34% non-ATG patients and
M. Robin et al.
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Table 1. Patient, disease and transplant characteristics.
                                                                  No ATG                 ATG              P value
Total number                                                          152                         135                         
Median age, years (IQR)                              56 (50-61)            58 (51-62)               0.07
Recipient gender                                                                                                             0.53
Male (%)                                                          100 (66)                 94 (70)
Female (%)                                                       52 (34)                  41 (30)
Median time from diagnosis                       41 (15-120)            30 (9-84)                0.13
to transplant in months (IQR)
Disease                                                                                                                               0.07
Primary myelofibrosis (%)                            97 (64)                  83 (61)
Secondary myelofibrosis (%)                       44 (29)                  50 (37)
Transformation into AML (%)                       11 (7)                     3 (2)
Date of transplantation                                                                                                  0.02
Before 2010                                                       52 (34)                  29 (21)
2010 and after                                                  100 (66)                106 (79)
Splenectomy before transplant (%)             42 (38)                   12 (9)               <0.0001
Lille score                                                                                                                          0.58
Low                                                                     30 (20)                  31 (23)
Intermediate                                                    78 (51)                  58 (43)
High                                                                     44 (29)                  46 (34)
DIPSS score                                                                                                                     0.018
Low                                                                     21 (18)                    6 (6)
Intermediate-1                                                 27 (23)                  24 (25)
Intermediate-2                                                 45 (39)                  32 (34)
High                                                                     23 (20)                  32 (34)
Missing                                                                   36                           41
Conditioning regimen                                                                                                < 0.0001
TBI-cyclophosphamide or fludarabine        30 (20)                  2 (1.5)
Busulfan-cyclophosphamide                          18 (12)                  2 (1.5)
Fludarabine-busulfan±other                         37 (24)                 110 (81)
Fludarabine-melphalan±other                      62 (41)                  14 (10)
FLAMSA                                                                 3 (2)                      7 (5)
Fludarabine-thiotepa                                         2 (1)                          0
GvHD prophylaxis                                                                                                         <0.0001
Calcineurin inhibitor alone                             8 (5)                    39 (29)
Calcineurin inhibitor and methotrexate    63 (42)                  47 (35)
Calcineurin inhibitor and MMF                    75 (49)                  46 (34)
Other                                                                   4 (3)                      3 (2)
Missing                                                               1 (0.6)                        0
Recipient CMV serostatus                                                                                             0.90
Positive                                                               95 (63)                  82 (61)
Negative                                                             57 (37)                  52 (39)
Missing                                                                    0                             1
Conditioning regimen                                                                             
Reduced intensity                                          115 (76)                113 (84)                0.11
TBI-based                                                          39 (26)                    3 (2)                <0.0001
Source of stem cells                                                                                                   <0.0001
Marrow                                                               26 (17)                    3 (2)
Blood                                                                 126 (83)                132 (98)
Gender                                                                                                                               0.38
Male recipient / female donor                     37 (24)                  44 (32)
Male recipient / male donor                         63 (41)                  50 (37)
Female recipient / female donor                 21 (14)                  20 (15)
Female recipient / male donor                    31 (20)                  21 (16)
Karnosfsky score, median [range]           90 [80-100]          90 (80-100]
80% or more, n (%)                                    142/147 (96%)     116/124 (93%)           0.27
ATG: antilymphocyte globulin; IQR: interquartile range; AML: acute myeloid leukemia; DIPSS:
Dynamic International Prognostic Scoring System; TBI: total body irradiation; FLAMSA: fludara-
bine, cytarabine and amascrine reduced intensity conditioning; GvHD: graft-versus-host disease;
MMF: mycophenolate mofetil; CMV: cytomegalovirus.
29% in ATG patients. The 5-year overall survival (54.7%
versus 52.8%), disease-free survival (49% versus 44.7%),
and GRFS (29.3% versus 23.6%) rates were not significant-
ly different between the two groups on univariate analysis
(Table 2).
Effects of antithymocyte globulin
Due to disparities between the ATG and non-ATG
groups, univariate analysis gave no clues on the effects of
ATG. A multivariable model was generated to analyze the
potential role of ATG on outcomes (Online Supplementary
Table S1). Age was the strongest variable significantly
associated with overall survival, disease-free survival and
non-relapse mortality. Adjustments were made for age at
transplantation, Lille score, Karnofsky Performance Status
score, splenectomy before transplant, intensity of condi-
tioning regimen (reduced intensity versus myeloablative)
and source of stem cells (bone marrow versus peripheral
blood). There was no effect of center on any outcome
(Online Supplementary Table S2). Table 3 shows the effect
of ATG for each outcome. The hazard ratio (HR) showed
a benefit from ATG on overall survival (HR: 0.66, 95% CI:
0.43-1.00; P=0.05) and non-relpase mortality (HR: 0.64,
95% CI: 0.39-1.07; P=0.09). The incidence of grade II-IV
acute GvHD was significantly lower following the use of
ATG (HR: 0.54, 95% CI: 0.34-0.86; P=0.01) but this was
not the case for either grade III-IV acute GvHD or chronic
extensive GvHD. In this model, ATG did not have a sig-
nificant impact on disease-free survival, GRFS or relapse
risk (see values in Table 3). Figure 2 shows the overall sur-
vival, disease-free survival and GRFS taking into account
variables of the adjusted model.
Discussion
While there is some evidence that in vivo ATG can pro-
tect against the occurrence of acute and chronic GvHD,
which may translate into a higher probability of GRFS in
patients transplanted from an HLA matched related
donor,19 there are no specific data from patients with
myelofibrosis undergoing HSCT, because of the small
numbers of such patients. In this retrospective study on
behalf of the EBMT, we analyzed the impact of ATG in
the largest documented cohort of patients with myelofi-
brosis transplanted with an HLA-matched related donor.
Approximately half of the patients received ATG which is
higher percentage than that previously reported by the
Center for International Blood and Marrow Transplant
Research (CIBMTR), according to which only 11% of
ATG in myelofibrosis patients
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Figure 1. Acute and chronic graft-versus-host disease. The top panels show the incidences of grade II-IV and grade III-IV acute chronic graft-versus-host disease
(GvHD). The bottom panels show the incidences of chronic GvHD and chronic extensive GvHD.
patients with a matched related donor received ATG.22
ATG was used less frequently before 2010 (35% versus
51%). The majority of patients received a reduced intensi-
ty conditioning regimen and the preferred source of stem
cells was peripheral blood. Our study demonstrated that
acute GvHD was decreased following the use of ATG but
there was no impact on chronic GvHD. The lack of atten-
uation of the risk of chronic GVHD is in contrast to the
findings of the randomized trial comparing ATG versus no
ATG in the setting of matched related donor HSCT pub-
lished recently by Kröger et al.19 However, that study
included patients with acute leukemia who were given
myeloablative conditioning whereas our cohort received
predominantly reduced intensity conditioning regimens
and the study focused only on myelofibrosis. Of note, the
rate of acute GvHD, even in patients who received ATG,
was relatively high in our cohort (26%) as compared to
that in the prospective study cited above but not dissimi-
lar to the rates in other studies including only patients
with myelofibrosis.17,18 The rates of chronic GvHD were
significantly high even after ATG; indeed, they were high-
er than previously reported in this disease setting. This
raises the question of whether these myelofibrosis
patients were more susceptible to developing chronic
GvHD. We could postulate that these patients, who still
had myelofibrosis slowly resolving in the first months
after transplantation, had a pro-inflammatory profile able
to trigger GvHD. Indeed, myelofibrosis is associated with
elevated pro-inflammatory biomarkers  such as those
found in both autoimmune disease and immune dysregu-
lation23–26 and it has been demonstrated that the bone mar-
row remains fibrotic at 3 months following HSCT in
approximately half of patients.27 Moreover, Hussain et al.
reported that even in patients in whom fibrosis resolved
following HSCT, the levels of pro-inflammatory cytokines
and tissue remodeling factors could remain elevated.28 In
contrast, other cytokines are downregulated following
HSCT, such as the T-cell inhibitory receptor Tim-3 (T-cell
M. Robin et al.
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Table 2. Outcomes in patients with or without T-cell depletion (univariate).
Outcomes: number of events    No ATG                          ATG                P value
                                                  (n=152)                      (n=135)                  
Neutrophil recovery                           143                                    130               Gray: P=0.35
60-day cum incidence            94.1% (88.7-96.9)           96.3% (90.9-98.5)              
Platelet recovery                                 104                                    108               Gray: P=0.09
180-day cum incidence          68.4% (60.3-75.2)           80.3% (72.3-86.1)
Grade II-IV acute GvHD                     58                                      32              Gray: P=0.0067
4-month cum incidence        41.4% (33.1-49.5)           26.2% (18.7-34.3)
Grade III-IV acute GVHD                   18                                      20               Gray : P=0.47
4-month cum incidence         11.9% (7.3-17.6)             15.1% (9.6-21.7)
Chronic GvHD*                                     75                                      62                Gray: P=0.47
5-year cum incidence            51.7% (43.1-59.6)           54.6% (44.5-63.7)
Extensive chronic GvHD *                 37                                      33                Gray: P=0.50
5-year cum incidence            25.8% (18.9-33.3)           28.3% (20.4-36.7)
Relapse                                                  24                                      29               Gray: P=0.083
5-year cum incidence            18.6% (12.1-26.1)          24.4% (16.5-33.1)
Non-relapse mortality                         45                                      31                Gray: P=0.56
5-year cum incidence            32.5% (24.4-40.7)           31.0% (20.9-41.6)
Death                                                      65                                      44             Logrank P=0.43
Median (95% CI)               63.4 months (39.8-NA)  64 months (44.7-NA)
5-year OS                                  54.7% (45.1-63.1)           52.8% (42.1-66.3)
Cause of death                                                                                                   Fisher exact:
                                                                                                                                      P=0.52
Relapse/progression                    22 (34%)                         13 (29%)
Other                                                35 (54%)                         28 (64%)
Unknown                                           8 (12%)                            3 (7%)
Relapse or death                                  69                                      60            Log-rank: P=0.46
Median (95% CI)                 59.5 months (29-NA)  38.1 months (23.6-NA)
5-year DFS                                49.0% (40.6-59.0)           44.7% (34.7-57.4)              
GvHD relapse death                            95                                      86            Log-rank: P=0.12
Median (95% CI)                9.9 months (8.2-17.7)   7.5 months (6.7-11.3)
5-year GRFS                             29.3% (22.0-38.9)           23.6% (15.8-35.2)              
*censored at donor lymphocyte infusion. ATG: antilymphocyte globulin; cum incidence: cumu-
lative incidence; GvHD: graft-versus-host disease; OS: overall survival; DFS: disease-free survival;
GRFS: GvHD-free, relapse-free survival.
Figure 2. Adjusted survival curves. From left to right, overall survival (OS), disease-free survival (DFS), and graft-versus-host disease-free, relapse-free survival (GRFS)
in patients who were given antilymphocyte globulin (red) and patients who were not given antilymphocyte globulin (black) with the 95% confidence intervals (dotted
lines). Curves have been adjusted according to multiple Cox models.
immunoglobulin and mucin-domain containing-3), which
may play a role in the control of GvHD.28,29
While ATG clearly decreased the risk of acute GvHD,
the adjusted model showed a trend towards improved
overall survival in patients who received ATG (P=0.05).
This higher risk of mortality without ATG may be
explained by higher risk of acute GvHD even if the excess
of mortality was not observed only in the first months
post-transplant corresponding to GvHD. Treatment of
GvHD and steroid-refractory GvHD may have con-
tributed to mortality in patients who did not receive ATG.
Of note, the definitions of acute and chronic GvHD in the
registry were still restricted to the time of development of
the disease, such that GvHD occurring in the 100 first
days was considered as acute GvHD but we had no data
regarding late acute GvHD which is considered as chronic
GvHD in this study. Indeed, the classification of acute and
chronic GvHD was not made according to the latest
National Institutes of Health (NIH) consensus and chronic
GvHD may have been overestimated because of the inclu-
sion of cases of late acute GvHD.30 Our analysis was based
on registry data and GvHD was not recoded a posteriori
according to the NIH classification. GRFS, which captures
both severe acute and severe chronic GvHD, is an impor-
tant endpoint in this setting and showed no difference
according to the use or not of ATG. Of note, even if the
risk of chronic GvHD is mostly influenced by previous
acute GvHD, other variables, such as the management of
immunosuppressive therapy and cellular therapy may
influence the risk of chronic GvHD. Finally, this is the first
study that shows a trend to lower mortality in patients
receiving ATG. Four prospective trials conducted in the
setting of transplantation from unrelated donors and the
aforementioned study in the matched sibling donor set-
ting did not find a significant overall survival advantage in
patients given ATG.19,31–33 In contrast, one large prospective
randomized trial found that overall survival was lower in
patients receiving ATG in the setting of unrelated donor
transplantation (whether given reduced intensity or mye-
loablative conditioning).34 It must be considered however
that the dose of ATG and the manufacturing process of
these products may also have an impact on outcomes and
differ in the various prospective trials. In the present
EBMT study, we were able to identify patients who
received Thymoglobulin® or Grafalon® but due to small
numbers in the subgroups, we could not draw conclusions
regarding the specific impact of the individual products on
outcomes. Absolute lymphocyte count may also con-
tribute to the efficiency of ATG and this factor could not
be studied here from the registry data.34 We can only pos-
tulate that myelofibrosis patients, who usually have not
received intensive chemotherapy, may arrive at transplan-
tation with subnormal lymphocyte counts, which can be
targeted by ATG. With regards to relapse risk, it was not
confirmed in the multivariable model that ATG increased
the risk of relapse; however, relapse continued to occur
late after HSCT without a real plateau occurring, high-
lighting the importance of long-term monitoring in
myelofibrosis patients who undergo HSCT.
In conclusion, this retrospective data analysis of
myelofibrosis patients undergoing HSCT whose data
were included in the EBMT registry confirms that in vivo
ATG is able to protect against acute GvHD and possibly
may decrease mortality rates. A prospective study is need-
ed to confirm the role of ATG in myelofibrosis patients
transplanted from an HLA-matched related donor.
ATG in myelofibrosis patients
haematologica | 2019; 104(6) 1235
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